References
- Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559–1565. doi:10.1016/j.jaad.2020.04.183
- Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83(1):39–45. doi:10.1016/j.jaad.2020.03.049
- Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382(8):706–716. doi:10.1056/NEJMoa1908316
- Luo Y, Kuai L, Song N, et al. Efficacy and safety of fire needle therapy for nodular prurigo: a quantitative study. Evid Based Complement Alternat Med. 2019;2019:8797056. doi:10.1155/2019/8797056
- Haomiao B, Yan L, Liuliu Z, et al. Regulation mechanism of itch. J Neuroanat. 2020;36(06):679–684.